GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (AQSE:MYIG) » Definitions » Shiller PE Ratio

Mydecine Innovations Group (AQSE:MYIG) Shiller PE Ratio : (As of Oct. 31, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mydecine Innovations Group Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mydecine Innovations Group Shiller PE Ratio Historical Data

The historical data trend for Mydecine Innovations Group's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Shiller PE Ratio Chart

Mydecine Innovations Group Annual Data
Trend Aug14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mydecine Innovations Group Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mydecine Innovations Group's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Mydecine Innovations Group's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mydecine Innovations Group's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mydecine Innovations Group's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Mydecine Innovations Group's Shiller PE Ratio falls into.



Mydecine Innovations Group Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Mydecine Innovations Group's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, Mydecine Innovations Group's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.023/127.5217*127.5217
=-0.023

Current CPI (Jun. 2024) = 127.5217.

Mydecine Innovations Group Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201408 0.000 99.315 0.000
201412 -12.468 98.367 -16.163
201503 -23.859 99.789 -30.490
201506 -46.729 100.500 -59.293
201509 -5.055 100.421 -6.419
201512 -21.921 99.947 -27.969
201603 -3.583 101.054 -4.521
201606 -12.285 102.002 -15.359
201609 -7.838 101.765 -9.822
201612 -121.601 101.449 -152.854
201703 -40.842 102.634 -50.746
201706 -39.653 103.029 -49.080
201709 -3.753 103.345 -4.631
201712 -104.978 103.345 -129.537
201803 -25.165 105.004 -30.562
201806 -64.522 105.557 -77.948
201809 -7.165 105.636 -8.649
201812 -70.263 105.399 -85.011
201903 -5.960 106.979 -7.104
201906 -1.484 107.690 -1.757
201909 -1.220 107.611 -1.446
201912 -16.180 107.769 -19.146
202003 -0.289 107.927 -0.341
202006 -1.474 108.401 -1.734
202009 -2.334 108.164 -2.752
202012 -2.352 108.559 -2.763
202103 -0.740 110.298 -0.856
202106 -1.021 111.720 -1.165
202109 -0.540 112.905 -0.610
202112 -1.310 113.774 -1.468
202203 -0.719 117.646 -0.779
202206 -0.222 120.806 -0.234
202209 -0.026 120.648 -0.027
202212 0.112 120.964 0.118
202303 -0.337 122.702 -0.350
202306 -0.060 124.203 -0.062
202309 -0.938 125.230 -0.955
202312 -0.197 125.072 -0.201
202403 -0.012 126.258 -0.012
202406 -0.023 127.522 -0.023

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mydecine Innovations Group  (AQSE:MYIG) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Mydecine Innovations Group Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mydecine Innovations Group Business Description

Traded in Other Exchanges
Address
1890 – 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group Headlines

No Headlines